{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:57:46Z","timestamp":1778399866539,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"The National Commission for Scientific and Technological Research"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jval.2020.05.014","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T11:47:32Z","timestamp":1596282452000},"page":"1256-1267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"David","family":"Aceituno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Pennington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Iruretagoyena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Matthew","family":"Prina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"McCrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.05.014_bib1","first-page":"2125","article-title":"Employment and the associated impact on quality of life in people diagnosed with schizophrenia","volume":"11","author":"Bouwmans","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11126-019-09633-4","article-title":"Quality of life in schizophrenia: a meta-analysis of comparative studies","volume":"90","author":"Dong","year":"2019","journal-title":"Psychiatr Q"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","article-title":"Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies","volume":"211","author":"Lally","year":"2017","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.bp.114.158931","article-title":"Shared treatment decision-making and empowerment-related outcomes in psychosis: systematic review and meta-analysis","volume":"209","author":"Stovell","year":"2016","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2020.05.014_bib6","series-title":"The Abandoned Illness: A Report from the Schizophrenia Commission","year":"2012"},{"key":"10.1016\/j.jval.2020.05.014_bib7","doi-asserted-by":"crossref","first-page":"g1173","DOI":"10.1136\/bmj.g1173","article-title":"Management of psychosis and schizophrenia in adults: summary of updated NICE guidance","volume":"348","author":"Kuipers","year":"2014","journal-title":"BMJ"},{"issue":"9590","key":"10.1016\/j.jval.2020.05.014_bib8","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(07)61239-2","article-title":"Resources for mental health: scarcity, inequity, and inefficiency","volume":"370","author":"Saxena","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2020.05.014_bib9","series-title":"NICE DSU Technical Support Document 9: The Identification, Review and Synthesis of Health State Utility Values from the Literature","author":"Papaioannou","year":"2011"},{"key":"10.1016\/j.jval.2020.05.014_bib10","volume":"4","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jval.2020.05.014_bib11","series-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"Brazier","year":"2017"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR Good Practices for Outcomes Research Task Force report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jval.2011.04.006","article-title":"How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review","volume":"14","author":"Papaioannou","year":"2011","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib14","article-title":"Systematic review of pharmacoeconomic models for schizophrenia","volume":"6","author":"Zhou","year":"2018","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14737167.2018.1430571","article-title":"A\u00a0systematic review of health economic models and utility estimation methods in schizophrenia","volume":"18","author":"N\u00e9meth","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.jval.2020.05.014_bib16","first-page":"1187","article-title":"Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands","volume":"20","author":"Einarson","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"suppl 1","key":"10.1016\/j.jval.2020.05.014_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40273-017-0547-8","article-title":"The identification, review and synthesis of health state utility values from the literature","volume":"35","author":"Ara","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.jval.2020.05.014_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2165\/11537300-000000000-00000","article-title":"A\u00a0review and critique of studies reporting utility values for schizophrenia-related health states","volume":"28","author":"Mavranezouli","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.jval.2020.05.014_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.jval.2020.05.014_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40273-018-0670-1","article-title":"A\u00a0practical guide to conducting a systematic review and meta-analysis of health state utility values","volume":"36","author":"Petrou","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ebmental-2019-300089","article-title":"Health state utility values in schizophrenia: protocol for a systematic review and meta-analysis","volume":"22","author":"Aceituno","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/S0266462317000897","article-title":"Performance of Ovid Medline search filters to identify health state utility studies","volume":"33","author":"Arber","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"10.1016\/j.jval.2020.05.014_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40273-015-0310-y","article-title":"Is meta-analysis for utility values appropriate given the potential impact different elicitation methods have on values?","volume":"33","author":"Peasgood","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3102\/10769986030003261","article-title":"Bias and efficiency of meta-analytic variance estimators in the random-effects model","volume":"30","author":"Viechtbauer","year":"2005","journal-title":"J\u00a0Educ Behav Stat"},{"issue":"7414","key":"10.1016\/j.jval.2020.05.014_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib26","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"issue":"2","key":"10.1016\/j.jval.2020.05.014_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2003.10.010","article-title":"Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores","volume":"71","author":"Lenert","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2020.05.014_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.jval.2020.05.014_bib30","first-page":"101","article-title":"Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists","volume":"11","author":"Revicki","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jval.2020.05.014_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1477-7525-12-48","article-title":"Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions","volume":"12","author":"Matza","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2020.05.014_bib32","first-page":"17","article-title":"The side effects of antipsychotic drugs and patients\u2019 quality of life: patient education and preference assessment with computers and multimedia","author":"Morss","year":"1993","journal-title":"Proc Annu Symp Comput Appl Med Care"},{"key":"10.1016\/j.jval.2020.05.014_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-10-35","article-title":"Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study","volume":"10","author":"Osborne","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/oxfordjournals.schbul.a006903","article-title":"Contingency valuation and preferences of health states associated with side effects of antipsychotic medications in schizophrenia","volume":"27","author":"Sevy","year":"2001","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib35","first-page":"118","article-title":"[Measuring preferences of psychiatric patients]","volume":"31","author":"K\u00f6nig","year":"2004","journal-title":"Psychiatr Prax"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00019053-200017030-00005","article-title":"Assessing health utilities in schizophrenia. A feasibility study","volume":"17","author":"Voruganti","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jval.2020.05.014_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205223","article-title":"What utility scores do mental health service users, healthcare professionals and members of the general public attribute to different health states? A co-produced mixed methods online survey","volume":"13","author":"Flood","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2020.05.014_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12888-016-0930-6","article-title":"The effect of the medicine administration route on health-related quality of life: results from a time trade-off survey in patients with bipolar disorder or schizophrenia in 2 Nordic countries","volume":"16","author":"J\u00f8rgensen","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"11","key":"10.1016\/j.jval.2020.05.014_bib39","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.jval.2020.05.014_bib40","first-page":"203","article-title":"A\u00a0general health policy model: update and applications","volume":"23","author":"Kaplan","year":"1988","journal-title":"Health Serv Res"},{"issue":"3 suppl","key":"10.1016\/j.jval.2020.05.014_bib41","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00005650-198903001-00003","article-title":"The Quality of Well-being Scale. Applications in AIDS, cystic fibrosis, and arthritis","volume":"27","author":"Kaplan","year":"1989","journal-title":"Med Care"},{"issue":"2-3","key":"10.1016\/j.jval.2020.05.014_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0165-1781(96)02797-7","article-title":"Quality of well-being in late-life psychosis","volume":"63","author":"Patterson","year":"1996","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-1781(01)00260-8","article-title":"Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients","volume":"103","author":"Kasckow","year":"2001","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.jval.2020.05.014_bib44","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.MLR.0000044900.72470.D4","article-title":"Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia","volume":"41","author":"Pyne","year":"2003","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/schbul\/sbp121","article-title":"Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness","volume":"37","author":"Valenstein","year":"2011","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.psychres.2013.01.016","article-title":"Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures","volume":"209","author":"Thwin","year":"2013","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1287\/opre.30.6.1043","article-title":"Application of multi-attribute utility theory to measure social preferences for health states","volume":"30","author":"Torrance","year":"1982","journal-title":"Oper Res"},{"key":"10.1016\/j.jval.2020.05.014_bib48","unstructured":"Williams A. A measurement and validation of health: a chronicle. Centre for Health Economics, University of York. https:\/\/ideas.repec.org\/p\/chy\/respap\/136chedp.html. Accessed July 26,\u00a02019."},{"issue":"8","key":"10.1016\/j.jval.2020.05.014_bib49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0924-9338(01)00609-5","article-title":"Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics","volume":"16","author":"Dernovsek","year":"2001","journal-title":"Eur Psychiatry"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00004714-199708000-00010","article-title":"Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol","volume":"17","author":"Chouinard","year":"1997","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib51","first-page":"199","article-title":"Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis","volume":"8","author":"Oh","year":"2001","journal-title":"Can J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib52","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2020.05.014_bib53","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/MLR.0b013e31814848f1","article-title":"US norms for six generic health-related quality-of-life indexes from the National Health Measurement study","volume":"45","author":"Fryback","year":"2007","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.jval.2020.05.014_bib54","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/0272989X14524990","article-title":"Utility values for adults with unipolar depression: systematic review and meta-analysis","volume":"34","author":"Mohiuddin","year":"2014","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib55","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/acps.12074","article-title":"Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis","volume":"127","author":"Challis","year":"2013","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib56","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11136-015-1120-6","article-title":"Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC","volume":"25","author":"Siani","year":"2016","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/0272989X07300604","article-title":"A\u00a0review and meta-analysis of prostate cancer utilities","volume":"27","author":"Bremner","year":"2007","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib58","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0272989X14536779","article-title":"A\u00a0review and meta-analysis of colorectal cancer utilities","volume":"34","author":"Djalalov","year":"2014","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib59","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/01.STR.32.6.1425","article-title":"The utility of health states after stroke: a systematic review of the literature","volume":"32","author":"Post","year":"2001","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib60","article-title":"Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results","volume":"7","author":"Zhou","year":"2019","journal-title":"J\u00a0Mark Access Health Policy"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.2017.10","article-title":"Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties","volume":"212","author":"Keetharuth","year":"2018","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2020.05.014_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-7-84","article-title":"Quality of life in caregivers of patients with schizophrenia: a literature review","volume":"7","author":"Caqueo-Ur\u00edzar","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2020.05.014_bib63","series-title":"Pharmacoeconomic Evaluations of Clozapine in Treatment-Resistant Schizophrenia and Risperidone in Chronic Schizophrenia","author":"Glennie","year":"1997"},{"issue":"9","key":"10.1016\/j.jval.2020.05.014_bib64","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00005650-199709000-00004","article-title":"Measurement of the validity of utility elicitations performed by computerized interview","volume":"35","author":"Lenert","year":"1997","journal-title":"Med Care"},{"issue":"10","key":"10.1016\/j.jval.2020.05.014_bib65","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00005650-200010000-00005","article-title":"Differences in health values among patients, family members, and providers for outcomes in schizophrenia","volume":"38","author":"Lenert","year":"2000","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib66","first-page":"128","article-title":"[Quality of life instruments and health state preferences to assess effects of medical interventions for mentally and medically ill patients]","volume":"31","author":"Roick","year":"2004","journal-title":"Psychiatr Prax"},{"issue":"11","key":"10.1016\/j.jval.2020.05.014_bib67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00127-002-0587-y","article-title":"Quality of life assessment in people living with psychosis","volume":"37","author":"Herrman","year":"2002","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"10.1016\/j.jval.2020.05.014_bib68","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1192\/bjp.184.4.346","article-title":"Relapse in schizophrenia: costs, clinical outcomes and quality of life","volume":"184","author":"Almond","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2020.05.014_bib69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-4-10","article-title":"What is the value of social values? The uselessness of assessing health-related quality of life through preference measures","volume":"4","author":"Prieto","year":"2004","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.jval.2020.05.014_bib70","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11136-004-0689-y","article-title":"Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL","volume":"14","author":"van de Willige","year":"2005","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.jval.2020.05.014_bib71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s11136-006-0020-1","article-title":"The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D","volume":"15","author":"Saarni","year":"2006","journal-title":"Qual Life Res"},{"issue":"5","key":"10.1016\/j.jval.2020.05.014_bib72","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s11136-005-5745-8","article-title":"A\u00a0study of the construct validity of the Health Utilities Index Mark 3 (HUI3) in patients with schizophrenia","volume":"15","author":"Luo","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.05.014_bib73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.jval.2020.05.014_bib74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eurpsy.2006.08.004","article-title":"Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders","volume":"22","author":"K\u00f6nig","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eurpsy.2007.02.003","article-title":"Economic consequences of alternative medication strategies in first episode non-affective psychosis","volume":"22","author":"Stant","year":"2007","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11126-006-9026-7","article-title":"Measuring patient quality of life: is the health utility index useful?","volume":"78","author":"Tempier","year":"2007","journal-title":"Psychiatr Q"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib77","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1524-4733.2007.00280.x","article-title":"A\u00a0randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine","volume":"11","author":"Davies","year":"2008","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib78","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1524-4733.2008.00495.x","article-title":"Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) Study","volume":"12","author":"Alonso","year":"2009","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib79","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2009.03.041","article-title":"Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis","volume":"112","author":"Barton","year":"2009","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib80","first-page":"27","article-title":"A\u00a0comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia","volume":"12","author":"McCrone","year":"2009","journal-title":"J\u00a0Ment Health Policy Econ"},{"issue":"6","key":"10.1016\/j.jval.2020.05.014_bib81","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hup.1143","article-title":"Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study","volume":"25","author":"Adrianz\u00e9n","year":"2010","journal-title":"Hum Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jval.2020.05.014_bib82","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1192\/bjp.bp.109.076489","article-title":"Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders","volume":"197","author":"Saarni","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib83","first-page":"187","article-title":"Does the EQ-5D measure quality of life in schizophrenia?","volume":"14","author":"Halling Hastrup","year":"2011","journal-title":"J\u00a0Ment Health Policy Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib84","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jval.2010.11.016","article-title":"Estimation of a multiattribute utility function for the Spanish version of the TooL questionnaire","volume":"14","author":"Montejo","year":"2011","journal-title":"Value Health"},{"issue":"2-3","key":"10.1016\/j.jval.2020.05.014_bib85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.schres.2013.07.014","article-title":"Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jval.2020.05.014_bib86","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.socscimed.2013.09.019","article-title":"Operationalising the capability approach for outcome measurement in mental health research","volume":"98","author":"Simon","year":"2013","journal-title":"Soc Sci Med"},{"issue":"12","key":"10.1016\/j.jval.2020.05.014_bib87","first-page":"853","article-title":"Utility decrements associated with side effects in schizophrenia","volume":"17","author":"Millier","year":"2014","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2020.05.014_bib88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-7525-12-6","article-title":"Quality of life impact of mental health conditions in England: results from the adult psychiatric morbidity surveys","volume":"12","author":"Roberts","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.psychres.2013.10.002","article-title":"EQ-5D as a measure of programme outcome: results from the Singapore early psychosis intervention programme","volume":"215","author":"Subramaniam","year":"2014","journal-title":"Psychiatry Res"},{"issue":"10","key":"10.1016\/j.jval.2020.05.014_bib90","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s11136-015-0982-y","article-title":"How to interpret multidimensional quality of life questionnaires for patients with schizophrenia?","volume":"24","author":"Michel","year":"2015","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.jval.2020.05.014_bib91","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.4088\/JCP.14m09271","article-title":"Reductions in quality of life associated with common mental disorders: results from a nationally representative sample","volume":"76","author":"Penner-Goeke","year":"2015","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"49","key":"10.1016\/j.jval.2020.05.014_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21490","article-title":"Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness","volume":"21","author":"Barnes","year":"2017","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.jval.2020.05.014_bib93","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12888-017-1570-1","article-title":"Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion","volume":"17","author":"Heslin","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.jval.2020.05.014_bib94","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/eip.12481","article-title":"Cost-effectiveness of early intervention services for psychosis and fidelity to national policy\u00a0implementation guidance","volume":"12","author":"Radhakrishnan","year":"2018","journal-title":"Early Interv Psychiatry"},{"issue":"65","key":"10.1016\/j.jval.2020.05.014_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22650","article-title":"Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT","volume":"22","author":"Holt","year":"2018","journal-title":"Health Technol Assess"},{"issue":"8","key":"10.1016\/j.jval.2020.05.014_bib96","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jval.2018.02.012","article-title":"Health-related quality of life in people living with psychotic illness and factors associated with its variation","volume":"21","author":"Neil","year":"2018","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2020.05.014_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206236","article-title":"Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis","volume":"13","author":"Wijnen","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jval.2020.05.014_bib98","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S2215-0366(18)30388-2","article-title":"Cost-effectiveness of care for people with psychosis in the community and psychiatric hospitals in the Czech Republic: an economic analysis","volume":"5","author":"Winkler","year":"2018","journal-title":"Lancet Psychiatry"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520321264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520321264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:19:51Z","timestamp":1761095991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520321264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":98,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1098301520321264"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.05.014","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health State Utility Values in Schizophrenia: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}